4SC-203Phase I
Tyrosine-protein kinase receptor FLT3 inhibitor
AEE-788Phase I/II
Epidermal growth factor receptor erbB1 inhibitor
AGN-211745Phase II
VEGFR1 mRNA rnai inhibitor
choroidal neovascularization
AXITINIBApproved
Vascular endothelial growth factor receptor inhibitor
renal cell carcinoma
BMS-690514Phase II
Receptor protein-tyrosine kinase erbB-4 inhibitor
Chronic pain
BRIVANIBPhase III
Vascular endothelial growth factor receptor inhibitor
breast cancer
BRIVANIB ALANINATEPhase III
Vascular endothelial growth factor receptor inhibitor
hepatocellular carcinoma
CEDIRANIBApproved
Vascular endothelial growth factor receptor inhibitor
neoplasm
CEP-11981Phase I
Vascular endothelial growth factor receptor inhibitor
CEP-5214UNKNOWN
Vascular endothelial growth factor receptor inhibitor
DOVITINIBPhase III
Fibroblast growth factor receptor 3 inhibitor
renal cell carcinoma
FAMITINIBPhase III
Platelet-derived growth factor receptor inhibitor
gastrointestinal stromal tumor
FORETINIBPhase II
Stem cell growth factor receptor inhibitor
breast cancer
FRUQUINTINIBApproved
Vascular endothelial growth factor receptor inhibitor
GLESATINIBPhase II
Macrophage-stimulating protein receptor inhibitor
non-small cell lung carcinoma
IBCASERTIBPhase III
Serine/threonine-protein kinase Aurora-B inhibitor
small cell lung carcinoma
ICRUCUMABPhase I
Vascular endothelial growth factor receptor 1 antagonist
neoplasm
ILORASERTIBPhase II
Platelet-derived growth factor receptor inhibitor
KRN-633Phase I
Vascular endothelial growth factor receptor inhibitor
glioma
LENVATINIBApproved
Vascular endothelial growth factor receptor inhibitor
thyroid cancer
LENVATINIB MESYLATEApproved
Vascular endothelial growth factor receptor inhibitor
thyroid cancer
LINIFANIBPhase III
Tyrosine-protein kinase receptor FLT3 inhibitor
LUCITANIBPhase III
Fibroblast growth factor receptor 1 inhibitor
MOTESANIBPhase III
Platelet-derived growth factor receptor inhibitor
non-small cell lung carcinoma
NINTEDANIBApproved
Platelet-derived growth factor receptor inhibitor
idiopathic pulmonary fibrosis
NINTEDANIB ESYLATEApproved
Platelet-derived growth factor receptor inhibitor
idiopathic pulmonary fibrosis
OSI-930Phase I
Vascular endothelial growth factor receptor inhibitor
PAZOPANIBApproved
Fibroblast growth factor receptor 1 inhibitor
neoplasm
PAZOPANIB HYDROCHLORIDEApproved
Fibroblast growth factor receptor 1 inhibitor
soft tissue sarcoma
REGORAFENIBApproved
Discoidin domain-containing receptor 2 inhibitor
colorectal cancer
RG-1530Phase I
Fibroblast growth factor receptor 2 inhibitor
neoplasm
SEMAXANIBPhase III
Vascular endothelial growth factor receptor inhibitor
colorectal cancer
SORAFENIBApproved
Serine/threonine-protein kinase RAF inhibitor
renal cell carcinoma
SORAFENIB TOSYLATEApproved
Serine/threonine-protein kinase RAF inhibitor
renal cell carcinoma
SU-014813Phase II
Stem cell growth factor receptor inhibitor
breast cancer
SUNITINIBApproved
Macrophage colony stimulating factor receptor inhibitor
SUNITINIB MALATEApproved
Vascular endothelial growth factor receptor inhibitor
renal cell carcinoma
SURUFATINIBApproved
Fibroblast growth factor receptor 1 inhibitor
neoplasm
TAK-593Phase I
Platelet-derived growth factor receptor inhibitor
TELBERMINPhase II
Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist
diabetic foot
TG100-801Phase II
Ephrin type-B receptor 4 inhibitor
macular degeneration
TIVOZANIBApproved
Platelet-derived growth factor receptor beta inhibitor
renal cell carcinoma
TIVOZANIB HYDROCHLORIDEApproved
Platelet-derived growth factor receptor beta inhibitor
renal cell carcinoma
VANDETANIBApproved
Ephrin receptor inhibitor
VATALANIBPhase II
Platelet-derived growth factor receptor inhibitor
X-82Phase II
Platelet-derived growth factor receptor inhibitor
age-related macular degeneration
XL-820Phase II
Platelet-derived growth factor receptor inhibitor
XL-999Phase II
Platelet-derived growth factor receptor inhibitor
ovarian cancer